unknown
Stage
1
Investors
About
Alys Pharmaceuticals is a biotechnology company focused on immuno-dermatology; launched in February 2024, it consolidated assets from six companies to build an R&D-centric, multi-platform pipeline of dermatology therapeutics. The company is developing multiple programs and modalities to address unmet needs in dermatology.
Explore Alys Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.